TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Endocrine Outcome of Surgery for Pituitary Adenoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected symptomatic or progressively growing pituitary adenoma~* Informed consent~Exclusion Criteria:~* Prolactinoma~* No follow-up possible~* Emergency surgery without informed consent or without intraoperative MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- microsurgical technique (Type: ACTIVE_COMPARATOR): None
- endoscopic technique (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effectiveness of Certain Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants During Pregnancy and Evaluate Newborn Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant woman between 18 and 40 years of age~* Have depression as their only mental health disorder~* Have been receiving fluoxetine or citalopram for the treatment of depression for at least one month on the day of study entry for patients in the fluoxetine and citalopram arms, or no pharmacological treatment for patients in the control arm~* ≤ 26 weeks pregnant by estimated date of confinement~* Ability to give informed consent~* Singleton pregnancy~* Pregnant women no history of depression~Exclusion Criteria:~* Having any comorbid mental disorder other than generalized anxiety disorder as a secondary disorder~* History of or current epilepsy, endocrine, cardiac, pulmonary, renal or hepatic dysfunction that could negatively influence pregnancy and/or neonatal outcome~* Abusing alcohol or drugs~* Use of any self prescribed herbal treatments for depression

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Pregnant women currently taking Prozac for the treatment of depression
- 2 (Type: None): Pregnant women currently taking Zoloft for the treatment of depression
- 3 (Type: None): Pregnant women not currently using medication for the treatment of depression
- 4 (Type: None): Pregnant women with no history of, symptoms of, or treatment for depression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Relieving Acute Pain (RAP) Study: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* Admission to The Shock Trauma Center within 72 hrs~* Any trauma requiring inpatient opioid medication~* Plan by primary service to follow the Shock Trauma Guidelines for Acute Pain in Orthopedic Injury~* Predicted length of stay greater than or equal to 2 days~Exclusion Criteria:~* Non English speaking~* Spine cord injury~* Severe Traumatic brain injury (based on a Glascow Coma Scale of 8 or less)~* Patient-controlled analgesia~* Admission Creatinine \> 1.4~* History of chronic kidney disease~* Heroin use in the 3 months prior to admission (patient self-report)~* Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, mania, autism) and /or psychiatric condition leading to treatment and/or hospitalization within the last 1 year.~* Positive toxicology screen for methadone not prescribed during current hospitalization~* Pregnancy or breast feeding~* Contraindication to NSAIDs, including high risk of bleeding or known severe coronary artery disease~* Injuries deemed non survival.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Full Dose (FD) (Type: ACTIVE_COMPARATOR): Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
- PR (Partial Reinforcement) (Type: PLACEBO_COMPARATOR): Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
- C (Control) (Type: PLACEBO_COMPARATOR): Participants in this group will receive NSAIDs and placebo pills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects from 16 to 75 years, both inclusive~* Well-characterized focal epilepsy or epileptic syndrome~* Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period~* Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED ≤ 50% of the minimum recommended maintenance dose~Exclusion Criteria:~* Seizure type IA non-motor as only seizure type~* History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline~* Other serious uncontrolled disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Brivaracetam (BRV) 1 (Type: EXPERIMENTAL): 50 mg daily
- Brivaracetam (BRV) 2 (Type: EXPERIMENTAL): 100 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Individuals eligible to participate in this study must meet all the following inclusion criteria:~1. Participated in the SMA-001 study~2. Willing and able to provide written informed consent after the nature of the study has been explained and before the start of any research-related procedures.~3. Female patients of childbearing potential must have a negative pregnancy test (urine human chorionic gonadotropin \[HCG\] at the end of SMA-001 study); and must practice an effective, reliable contraceptive regimen during the study and for up to 30 days following discontinuation of treatment.~4. Ability to participate in the study based on overall health of the patient and disease prognosis, as applicable, in the opinion of the Investigator; and able to comply with all requirements of the protocol, including completion of study questionnaires.~Exclusion Criteria:~Individuals who met any of the exclusion criteria in the original protocol or those listed below are not eligible to participate in the study:~1. Epilepsy and currently on medication.~2. Uncontrolled asthma.~3. Concomitant use with sultopride.~4. Concomitant use with medicinal products with a narrow therapeutic window.~5. Concomitant use with medicinal products with a known to cause QTc prolongation.~6. Clinically significant abnormalities in 12 lead ECG, in the opinion of the Investigator.~7. Subjects with congenital QT syndromes.~8. Breastfeeding or pregnant at Screening or planning to become pregnant at any time during the study.~9. Intolerable amifampridine-related side effects~10. Treatment with an investigational drug (other than amifampridine) or device while participating in this study.~11. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confound the assessment of the patient.~12. History of drug allergy to any pyridine-containing substances or any amifampridine excipient(s).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- amifampridine phosphate (Type: EXPERIMENTAL): The dose of amifampridine was based on optimal neuromuscular benefit determined from the Run-in Period from SMA-001 or could be modified as the discretion of the Investigator. The maximum single dose was 20 mg. The dose range for patients 6 to 16 years of age was 15 to 60 mg, and for those 17 years and older the range was from 30 to 80 mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤80 years old~* Diagnosis of Multiple Myeloma~* Confirmed acute (MRI, a detectable low signal T1 ± oedema) painful vertebral compression fracture(s) VAS score is ≥6~* The patient is able to read and understand the Patient Information Sheet and study procedures~* The patient is able and willing to give written informed consent~Exclusion Criteria:~* Contraindications to anaesthesia~* Cord Compression or large epidural mass necessitating conservative management before balloon kyphoplasty~* Pain unrelated to vertebral collapse~* Infection at the site~* Presence of overt instability as judged by the principle investigator~* Known pregnancy at time of screening~* Severe Cardiopulmonary insufficiency~* Osteoblastic lesions~* Any co-morbidity, (e.g., diabetes, heart condition, obesity, psychiatric illness) which, in the opinion of the investigator, is of a severe enough nature to; interfere with the patient's ability to complete the study assessments; or present an unacceptable risk to the patient's safety to undergo study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 - Sham Procedure (Type: SHAM_COMPARATOR): Sham Procedure \& Conservative Treatment~Subjects will be blinded and randomised to Arm 1 and will undergo a general anaesthetic and undergo a sham procedure. They will also be treated under conservative management alone.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy~This is a non interventional as conservative treatment (standard of care for multiple myeloma patients) is used.
- Arm 2 - Balloon Kyphoplasty (Type: ACTIVE_COMPARATOR): Balloon Kyphoplasty \& Conservative Treatment - Interventional Arm~Subjects will be blinded and randomised to Arm 2 (balloon kyphoplasty) and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy~This is a interventional arm (balloon kyphoplasty procedure) and the patient will receive conservative treatment (standard of multiple myeloma patients) is used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exploration of Angiogenesis in Decompensated Developmental Venous Abnormalities

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Presenting a DVA requiring hyperselective catheterization~* Having sign an informed consent form~Exclusion Criteria:~* Presenting a contraindication to the realization of hyperselective cathterism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blood sample (Type: EXPERIMENTAL): Blood sampling Under general anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Chronotropic Incompetence (CI) Diagnostic Algorithm in Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for the case group:~* Patient is greater than 18 years of age and less than 70 years of old.~* Patient is willing and able to give informed consent.~* Patient has been diagnosed with stable chronic HF according to European Society of Cardiology 2012 HF guidance.~* New York Heart Association class I- III, including with HF with preserved ejection fraction and HF with reduced ejection fraction patients.~* Patients can perform moderate exercise.~* Left ventricular ejection fraction less than 55% but greater than 35%.~Inclusion criteria for the control group:~* Subject is greater than 18 years of age and less than 70 years of old.~* Subject is willing and able to give informed consent.~Exclusion criteria for the case group:~* Patient is unable or unwilling to sign the patient informed consent.~* Patient has implantable pacemaker, Implantable cardiovert defibrillator (ICD) or cardiac resynchronize therapy (CRT) device.~* Patient has at least one pacemaker, ICD or CRT indications.~* Patients has persistent atrial fibrillation (AF).~* Patient whose hear rate baseline at the rest is greater than 95 beats per minutes (BPM).~* Patient has contraindications for cardio-pulmonary exercise testing, including but not limited to, unstable angina, decompensated heart failure, active pericarditis or myocarditis and ECG ST-segment shift \> 2mm at the resting.~* New York Heart Association Class IV.~* Less than 45 days after myocardial infarction.~* Less than 3 months after acute heart failure.~* Patient has uncontrolled hypertension.~* Patient is pregnant.~* Patient has a medical condition that would limit study participation.~* Patient is enrolled in a concurrent study that may affect the outcome of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Case group (Type: EXPERIMENTAL): At the beginning of the study, each subject of the case group will complete echo examination and related lab test for BNP. During the study, each subject will have a six minutes' walk test and 24 hour ambulatory monitoring while having an ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. The treadmill test is optional to patients per physicians' instruction and/or patients' own judgment. It would be performed at the end of the study if chosen.
- Control group (Type: PLACEBO_COMPARATOR): Each subject of the control group will do the same test and examination with the subjects in the case group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age Health Care Worker~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Newsfeed (Type: ACTIVE_COMPARATOR): This will provide you with reliable accurate information on the pandemic.
- Gamification (Type: EXPERIMENTAL): The gamification function will allow users to earn points for actions completed. The gamification function has links to resources for infection control, watching or completing tasks or playing games to earn points. Points can be viewed at a facility level, state level or national level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PRISTINE - Personalised Approach to Improve aSThma prescrIbing iN childrEn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/Guardian/Participant is willing and able to give informed consent/assent~* Physician-diagnosed asthma that is inadequately controlled as per view of doctor (for example, history of at least two emergency visits to GP or hospital over the previous year, frequent use of blue inhaler (three times or more per week))~* Aged 5-11 years (inclusive)~* Children who are already on at least 400 micrograms per day inhaled beclomethasone or equivalent and hence ready to be prescribed inhaled long-acting beta2 agonists and/or other add-on medication or are already on inhaled long-acting beta2 agonists and/or other add-on medication~Exclusion Criteria:~* Parent/Guardian/Participant is unwilling or unable to give informed consent/assent~* Known contraindication to montelukast or salmeterol~* Other known significant airway or lung disease (e.g. chronic lung disease of prematurity, cystic fibrosis or congenital airway abnormalities) or other co-existing serious disease such as congenital cardiac disease~* Poor inhaler technique and/or history of poor adherence on checking following standard procedure at the clinic~* Participating in another clinical trial (other than observational trials and registries) concurrently or within 30 days prior to screening for entry into this study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Personalised Medicine (Type: EXPERIMENTAL): Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
- Standard Care (Type: NO_INTERVENTION): Standard of care (Standard Care will be prescribed controller medication based on guidelines)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Neuroimaging Analysis After Mild Traumatic Brain Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Applicable to all :~- Male 18 to 25 years, enrolled in French Social Security.~Group of mTBI patients:~- Diagnosis of mTBI in the last 2 weeks confirmed in emergency department of Bordeaux CHU, using the WHO definition (2004): head trauma ≤ 24h with Glasgow Coma Scale score of 13-15 and with one or more of the three symptoms following: confusion or disorientation, loss of consciousness for 30 minutes or less, posttraumatic amnesia for less than 24h.~Group of footballers:~- Member of the CFA and U19 teams of Girondins de Bordeaux.~Group of controls:~- Practicing regular physical activity (excluding combat or contact sports).~Exclusion Criteria :~* Abnormal neurological examination~* Drug addiction including alcohol Taking drugs targeting the central nervous system History of head trauma, or other notion of central nervous system injury~* History of severe high blood pressure, diabetes, chronic cardiovascular pathology, progressive or debilitating disease~* Subject unable to give informed consent~* Contraindication to MRI: head circumference\> 60 - Claustrophobia - Pacemaker, Implantable Neurostimulation, Implantable Defibrillator - Cochlear Implants - Ocular or cerebral ferromagnetic foreign body~* Refusal to be informed of an abnormality detected during MRI.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Brain Magnetic Resonance Imaging (MRI) (Type: EXPERIMENTAL): Neuroimaging protocol to assess brain changes after minor head trauma and over the time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy